Rebastinib
Cat. No.：YN440241
CAS No. ：1020172-07-9
规格
价格(RMB)
库存
| 产品名称: | Rebastinib |
| CAS No.: | 1020172-07-9 |
| Chemical Name: | 4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide |
| Synonyms: | DCC-2036 |
| 分子量: | 553.59 |
| 分子式: | C₃₀H₂₈FN₇O₃ |
| SMILES: | CC(C)(C)C1=NN(C(NC(NC2=C(F)C=C(OC3=CC(C(NC)=O)=NC=C3)C=C2)=O)=C1)C4=CC=C5C(C=CC=N5)=C4 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Rebastinib (DCC-2036) 是一种Bcr-Abl抑制剂抑制剂，作用于Abl1WT和Abl1T315I，IC50分别为 0.8 nM 和 4 nM，也抑制SRC，KDR，FLT3 和 Tie-2，低活性作用于c-Kit。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Chan, W.W., Wise, S.C., Kaufman, M.D., et al.Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036Cancer Cell.19(4),556-568(2011)
Eide, C.A., Adrian, L.T., Tyner, J.W., et al.The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profileCancer Res.71(9),3189-3195(2011)
Shen, Y., Shi, X., and Pan, J.The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRαPLoS One8(8),e73059(2013)
